Alder BioPharmaceuticals (ALDR) Tops Q4 EPS by 1c

Alder BioPharmaceuticals (NASDAQ: ALDR) reported Q4 EPS of $0.22, $0.01 better than the analyst estimate of $0.21. Revenue for the quarter came in at $6.4 million versus the consensus estimate of $5.7 million.

For earnings history and earnings-related data on Alder BioPharmaceuticals (ALDR) click here.

You May Also Be Interested In

• Berenberg Starts Lloyds TSB Group (LYG) at Hold, 'shares are fairly valued'
• SLM (SLM) Tops Q1 EPS by 20c; offers guidance
• Alamos Gold (AGI) Misses Q1 EPS by 1c